erlotinib hydrochloride has been researched along with Anaplastic Ependymoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouffet, E; Bowers, DC; Foley, MA; Gill, SC; Horan, J; Jakacki, RI; Kieran, MW; Wang, J; Zacharoulis, S | 1 |
| Gajjar, A; Wright, KD | 1 |
1 trial(s) available for erlotinib hydrochloride and Anaplastic Ependymoma
| Article | Year |
|---|---|
Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease-Free Survival; Ependymoma; Erlotinib Hydrochloride; Etoposide; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2016 |
1 other study(ies) available for erlotinib hydrochloride and Anaplastic Ependymoma
| Article | Year |
|---|---|
New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Erlotinib Hydrochloride; Gefitinib; Humans; Infant; Quinazolines; Treatment Outcome; Young Adult | 2009 |